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ABSTRACT
A patient with a history of autism spectrum disorder and epilepsy was hospitalized for management of
acute onset psychosis and agitation. The acuity of his behaviors warranted abrupt shifts in treatment and
multiple pharmacologic interventions were ineffective. The atypical nature of his presentation and intense
pressure from ancillary staff to consider organic etiologies drove frequent transitions of care within the
hospital setting. Multiple diagnoses were considered including a primary psychosis, excited catatonia and
antiepileptic drug-induced psychotic disorder. Ultimately the patient was diagnosed with bipolar disorder
and effectively treated with quetiapine and valproic acid. The authors suggest that rapid consideration of
comorbid bipolar disorder in autism spectrum disorder patients presenting with affective dysregulation
may expedite trial of an anticonvulsant with mood stabilizing properties, which would have simplified this
patient’s clinical course and limited potential for iatrogenic harm. This additional diagnosis and associated
course of treatment should be considered when a history of epilepsy and autism spectral disorder is
present with the symptom complex manifested in this patient.

INTRODUCTION:

Autism spectrum disorder (ASD) is a neurodevelopmental condition broadly characterized by deficits in
social interaction and restrictive patterns of behavior1. Although prevalence estimates for ASD have varied
across investigations, a 2014 study utilizing data from the Global Burden of Disease 2010 initiative
estimated a global population prevalence of approximately 7.6 cases of ASD per 1000 persons, and
established the importance of the condition as a major source of morbidity and disability within
populations2 . On an individual level ASD is a spectrum condition with tremendous clinical heterogeneity,
and mental health treatment of ASD is complicated by high rates of medical and psychiatric comorbidity.
Epilepsy, for example, is present in approximately 20% of individuals with an ASD3 . Within the domain
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of mental health, a comparative study of referrals to a pediatric psychopharmacology program
demonstrated that individuals with ASD (n = 217) had an average of 6 comorbid psychiatric diagnoses4 .
Accordingly, the targets and intensities of treatment often vary between ASD individuals.
Severe behavioral problems sometimes occur as part of the constellation of symptoms associated with
ASD. Classified under ‘irritability’ within ASD research literature, these disruptive behavioral problems
are particularly distressing to families, caregivers and providers and often emerge as targets of clinical
treatment. Suggestive of the scope of this problem, a multi-site research study in North America involving
1,380 children and adolescents with ASD found that 68% of patients had a history of physically aggressive
behavior towards a caregiver5 . The preponderance of research to-date on pharmacologic interventions for
irritability in ASD has focused on dopamine antagonists, or antipsychotic class medications. Historically,
the first generation (or “conventional”) antipsychotic haloperidol was most widely employed for this
purpose, though its contemporary use is more limited after studies demonstrated its association with high
rates of adverse dyskinesias in ASD individuals6 . Second generation (or “atypical”) antipsychotics are
now generally regarded as first-line agents for the irritability or ‘severely disruptive behavior’ symptom
cluster in ASD, with risperidone and aripiprazole having specific FDA approvals for this indication7 .
Evidence for other antipsychotic class medications, including olanzapine and quetiapine, has been mixed7.
An open-label trial in 2011 involving 11 patients with ASD demonstrated reductions in behavioral
agitation with administration of low-dose Quetiapine8 , though other studies have reported negative
findings.
With regard to other psychotropic agents, research into the efficacy of valproic acid (VPA) in the treatment
of ASD-related irritability was stimulated by a series of case reports which indicated that VPA-related
treatment of epilepsy comorbid to ASD was associated with improvements in other neurodevelopmental
symptom domains, in conjunction with a separate body of literature indicating the more general efficacy of
VPA in amelioration of aggression. Overall, studies-to-date indicate that VPA may be effective in treating
disruptive behavior associated with ASD, particularly in cases where ASD is associated with epilepsy
and/or other affective disorders.
This case study describes a patient with ASD, active epilepsy, and severe episodic affective dysregulation
whose clinical course was confounded by diagnostic uncertainty and notable for symptomatology
recalcitrant to several psychotropic trials. His symptoms, which were ultimately favored to be etiologically
related to comorbid bipolar disorder, remitted on a combination of VPA and quetiapine. The authors
suggest that rapid consideration of comorbid bipolar disorder in ASD patients presenting with affective
dysregulation may facilitate an expeditious trial of an anticonvulsant with mood stabilizing properties,
which would have simplified this patient’s clinical course and limited potential for iatrogenic harm. This
https://rdw.rowan.edu/crjcsm/vol2/iss1/5
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course of treatment should especially be considered where a history of active epilepsy is present.
PATIENT INFORMATION:
The patient was a 22 year-old man who was brought to the emergency department by his parents for
evaluation of multiple concerns including recent onset of psychosis, potential seizure activity and agitated
behaviors at home. The patient had a history of an autism spectrum disorder, epilepsy and depression.
The patient was diagnosed with autism spectrum disorder with borderline intellectual functioning at age 5.
Outside of episodes of depression, the patient had no other psychiatric history including no history of past
hospitalization, suicidality, psychosis or aggression towards others. He had no known history of substance
abuse or personal trauma. With family support, the patient was at baseline capable of completing tasks of
daily living and maintained employment at a job allocated for individuals with disabilities.
Collateral history acquired from informants (family members) served as the only reliable source of
information relating to his history of present illness and the patient’s parents provided a complex and
multifactorial recent history. Their story began 6 months ago, at which time the patient had been tapered
off his anti-epileptic, valproic acid, following a seizure-free period of several years. Several months later
the patient developed two generalized tonic-clonic seizures prompting initiation of topiramate. Shortly
thereafter, approximately 1 month prior to his current presentation, the patient began exhibiting paranoia
and marked irritable changes in his affect.
These changes in behavior led to interface with emergency services and two outside psychiatric
hospitalizations for psychosis in the month preceding his current presentation. Over the course of these
hospitalizations he was trialed on low-dose risperidone and quetiapine, in addition to replacement of
topiramate with lacosamide, then re-initiation of valproic acid as his primary anti-epileptic. None of these
interventions had been effective in ameliorating the patient’s agitation or psychosis and the family
presented to the emergency department in a state of ongoing crisis.
CLINICAL FINDINGS:
Initial evaluation with physical exam revealed ecchymosis across the chest and abdomen with extension to
the upper and lower extremities. This was associated with tenderness to palpation but no crepitus, gross
deformity or lacerating injuries. Neurologic exam did not reveal focal deficits, though assessment was
limited due to the patient’s distractibility and noncompliance. Heart and lung exam were normal and his
airway was patent. A comprehensive laboratory workup was notable for creatine kinase to 3500 U/L, liver
enzyme abnormalities (ALT/AST 109/155 U/L), a valproate level of 62.9 ug/mL and cardiac troponins of
0.026 ng/mL. All values were down trending on repeat assessment. A radiologic workup consisting of
2-view chest x-ray, non-contrast head CT and contrast CT of the chest were without any notable
abnormalities. An EKG was without ST-segment changes. The patient remained significantly agitated and
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disruptive in the emergency department and received two doses of 5 mg haloperidol, 2 mg lorazepam and
50 mg diphenhydramine with minimal improvement.
The patient exhibited threatening behavior in the emergency department and upon psychiatric ward
admission. On his first day of admission he was placed on assault precautions and required several
instances of locked seclusion and physical 4-point restraint. Antipsychotics were initially withheld due to
a differential diagnosis which included Neuroleptic Malignant Syndrome and agitation secondary to
extrapyramidal symptoms on the basis of the patient’s mask-life facies, bradykinesia and rigidity. An
agitated catatonia was also considered. Owing to ongoing laboratory evaluation which yielded elevated
C-reactive protein, the differential diagnosis was broadened to include central nervous system infection or
immune-mediated encephalopathy. Accordingly, the patient was transferred to the ICU for sedation and
acquisition of CSF studies – these were normal, including an assay for anti-NMDA receptor antibodies.
THERAPEUTIC INTERVENTIONS:
Observation on the inpatient psychiatric ward yielded target symptomatology which consisted of cognitive
disorganization, insomnia, a blunted but pressured affect, behavioral agitation, distractibility and profound
irritability. The patient was additionally observed to be hallucinating. The patient was initiated on
olanzapine but continued to exhibit a high tempo of behavioral dysregulation and minimal, fractured sleep.
Given clinical non-response to olanzapine over 4 days of treatment, during which over 60 mg of
olanzapine was administered, in conjunction with persistent mental status exam manifestations of
extrapyramidal symptoms, the decision was made to withhold further dopaminergic blockade and treat
with oral benzodiazepines in conjunction with clonidine and his maintenance dose of valproic acid. A
benzodiazepine challenge resulted in an initial positive response, but over subsequent days the patient’s
behavior again relapsed to a state of physical agitation and aggression without sustained improvement in
any other domains of symptomatology. His extrapyramidal symptoms also did not remit.
Following several instances of injury to the patient’s hospital attendants, as well as auxiliary staff burdens
including constant 2-to-3 person watches warranted by the patient’s highly disorganized behavior, a
difficult case conference was held and attended by representatives of multiple disciplines. Ultimately, a
plan was formulated which involved transfer to the ICU for dexmedatomidine sedation for medication
washout, based on the concern that this developmentally delayed patient was being disinhibited by the
rendered benzodiazepine treatments. A prolonged EEG was acquired during this wash-out period which
was negative for any epileptiform changes.
The patient’s symptoms were generally unimproved following the washout period and he was transferred
back to the psychiatric ward. A previously closed section of the ward was re-opened, allowing the patient
to be domiciled in an environment with less external stimuli and limited potential for harm towards other
https://rdw.rowan.edu/crjcsm/vol2/iss1/5
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patients in the hospital.
The patient was initiated on aggressively titrated quetiapine and his valproic acid dose was aggressively
increased from 1,000 to 2,000mg daily, resulting in a serum valproate level of 115.2 ug/mL. Additionally,
eslicarbazepine was added to his regimen after he exhibited a recurrence of seizure-like activity. On this
regimen the patient’s agitation and aggressive disorganized behavior gradually improved in a sustained
manner. His extrapyramidal symptoms, until this point a constant feature of his mental status exam,
resolved. After a complex hospitalization lasting almost three weeks, the patient was discharged home.
FOLLOW UP
Although the patient had follow-up outside of our direct hospital system, a review of his electronic
medical record verified ongoing and current prescription of quetiapine and valproic Acid. This is
interpreted by the authors as a measure of adherence and tolerability of these medications.

DISCUSSION

Autism spectrum disorder (ASD) is a neurodevelopmental condition with significant medical and
neuropsychiatric overlay, contributing to the potential for diagnostic and treatment challenges in the acute
care setting. Although there are multiple studies investigating the use of antipsychotics and other agents
for use in the treatment of behavioral agitation associated with ASD, there are fewer delineating the
pathways of treatment when ASD is comorbid with severe mental illness – a comorbidity which may be
more common than in the general population9 .
An important feature of the patient’s hospitalization were clinical concerns that his condition was being
prolonged or exacerbated by iatrogenic means – for example, agitation as a result of induction of severe
extrapyramidal symptoms associated with use of dopamine blocking agents. Akathisia in particular has
been shown to worsen psychopathology and exacerbate impulsive and aggressive behavior10 . The patient
exhibited autonomic and motor abnormalities with diaphoresis, tremulousness, Parkinsonism and rigidity
which did not respond to common interventions including withdrawal of antipsychotic therapy or
treatment with anticholinergics (benztropine) or benzodiazepines. Laboratory markers of elevated creatine
kinase and transaminitis, in conjunction with moments of urinary incontinence and other behaviors which
were regressed from baseline, raised concern for possible neuroleptic malignant syndrome. However, the
patient was afebrile for the duration of his hospital course and his vital signs remained stable during close
longitudinal observation. His symptoms also did not respond meaningfully to a benzodiazepine challenge,
as might be expected in an agitated catatonia.
The temporal relationship between initiation of a new anti-epileptic drug (AED) topiramate and onset of
the patient’s presenting symptomatology raised concern for antiepileptic drug-induced psychotic disorder
Published by Rowan Digital Works, 2020
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(AIPD), a known phenomenon but one without rigorously defined diagnostic or classification criteria.
Although initial clinical trial data did not identify a significant link between topiramate and anti-epileptic
drug induced psychosis11 , subsequent studies have provided evidence of a possible relationship12,13 .
However, in these cases of topiramate-induced psychosis, symptoms were noted to resolve rapidly with
drug discontinuation (generally within 48 hours) and this was inconsistent with the patient’s longer
duration of illness. Given the overall high index of suspicion for an organic etiology of illness, a rare
hyperammonemic encephalopathic condition related to co-treatment with topiramate and valproic acid was
also considered, though subsequent laboratory studies did not support this diagnosis14 . More recent
investigations into the phenomena of antiepileptic-induced psychosis have identified female gender,
temporal lobe involvement, a shorter duration of psychosis (less than 2 weeks) and use of levetiracetam as
statistically significant correlates of risk for this condition15 .
Case reports supporting use of valproic acid in individuals with ASD with affective dysregulation and
irritability have led to interrogation of the clinical utility of this medicine through more rigorous study
methodologies over time. J. Childs et al presented a case study of autistic twins treated with VPA for
management of absence seizures, who then exhibited global improvement of ASD-related
symptomatology16 . A case series of 3 children with ASD and electroencephalographic changes, but no
frank seizure disorder diagnoses, were noted to exhibit significant improvement in ASD-related behaviors
with VPA treatment17 . An additional case series involving VPA treatment of two patients with severe
intellectual disability, only one of whom had a potential seizure history, suggested a significant reduction
in the incidence of non-affective aggression18 . In 1993, an open prospective study involving use of VPA
to treat behavioral problems in patients with intellectual disability (n = 18) found that 78% of patients
responded favorably to treatment19 . In this study, a favorable response to treatment was especially
associated with a history of epilepsy or seizure. A retrospective study in 1999 investigating the effect of
divalproex sodium (a compound of sodium valproate and valproic acid) on aggression in adults with
intellectual disability (n = 28) found that a majority of treated patients exhibited significant reductions in
aggression20 . A retrospective study of divalproex sodium in 14 patients with DSM-IV Autism,
Asperger’s, or PDD NOS noted global improvement in various measures of ASD (including aggression) in
71% (n = 10) of patients21 . In this study, all patients with a history of a seizure disorder or abnormal EEG
readings were in the responder category. In 2005, a prospective double-blind placebo-controlled study
which randomized 30 patients with pervasive neurodevelopmental disorder to treatment or placebo failed
to identify a treatment difference between VPA and placebo groups22 . Notably, this study excluded
patients with a history of recent seizures or prior VPA trials. In 2010, a randomized, double-blind,
placebo-controlled study involving 55 ASD patients found that 63% of VPA but only 9% of placebo cases
https://rdw.rowan.edu/crjcsm/vol2/iss1/5
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responded with significant improvements in irritability, with a dose-dependent trend as assessed by VPA
levels23 . Subjects with “active or unstable epilepsy” were excluded. Overall, the preponderance of studies
indicate that VPA may be effective for ASD patients with irritability. This finding is consistent with the
pattern of treatment and symptom response observed in the case described in this report.

The patient evinced an array of symptomatology, but most prominently a disorganized and agitated affect,
hallucinations with reactivity to internal stimuli and profound irritability. These features led to an initial
conceptualization of primary psychosis. However, the totality of his clinical presentation, which included
degraded sleep, distractibility, pressured mannerisms, and clear periodicity – which is to say, his symptoms
were episodic and loosely circumscribed by initial and terminal boundaries beyond which the patient
appeared to be at his baseline – has led to a mixed-state mania as the most favorable diagnostic
conceptualization of this patient’s case. There is literature to suggest that rates of bipolar disorder are
significantly elevated in ASD. Specifically, the studies below indicate the importance of including a
bipolar disorder on the differential when treating ASD patients with episodic irritability with affective
dysregulation.

A study involving consecutive evaluation of patients referred to a pediatric psychopharmacology clinic
showed that 21% (n = 14) of patients with a DSM-III-R diagnosis of autism, pervasive development
disorder (PDD) and/or PDD NOS also met criteria for mania24 . In a follow up study, 30% (n = 47) of
patients with bipolar 1 disorder also met criteria for an ASD25 . Both of the aforementioned studies
involved children and adolescents only. In a study investigating ASD comorbidities in adult patients, 7%
(n = 9) of study subjects with ASD also met criteria for bipolar disorder with psychotic features26 . Finally,
a systematic review investigating the comorbidity of bipolar disorder with Asperger’s syndrome (a high
functioning ASD) estimated a comorbidity prevalence ranging from 6-21%9 . All of these estimates are
significantly higher than the approximate 1% prevalence of bipolar disorder in the general population27 .
Additionally, manias in the context of comorbid ASD may be significantly more likely to present in a
mixed (dysphoric/aggressive) state relative to the euphoric affect classically associated with this condition,
contributing to the potential for this diagnosis to be missed when comorbid in ASD individuals28 . The
diagnostic conceptualization of the patient’s case as one with comorbid ASD and bipolar disorder is also
consistent with the patient’s history of depression (often a historic affective precursor to frank mania) and
the improvement of his symptomatology with increase of his valproic acid dose, in conjunction with
aggressively titrated atypical antipsychotic medication.
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CONCLUSION

Multiple diagnoses were considered in this complex patient. Bipolar disorder with irritable mania was
ultimately favored as the most likely diagnosis. Bipolar disorder may be more common in patients with
autism spectrum disorder. Early treatment with mood stabilizing anticonvulsants should be considered in
ASD patients presenting with severe affective dysregulation, particularly when there is a history of
epilepsy.
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I am a military service member or employee of the U.S. Government. This work was prepared as part of
my official duties. Title 17, U.S.C. §105 provides that copyright protection under this title is not available
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